Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report)’s stock price shot up 5.9% during mid-day trading on Monday. The company traded as high as $31.18 and last traded at $31.1060. Approximately 5,710 shares were traded during mid-day trading, a decline of 94% from the average session volume of 94,543 shares. The stock had previously closed at $29.36.
Analysts Set New Price Targets
Several research firms have issued reports on NBTX. Guggenheim assumed coverage on Nanobiotix in a research report on Tuesday, September 15th. They set a “buy” rating and a $64.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, October 15th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $46.67.
Check Out Our Latest Stock Report on NBTX
Nanobiotix Stock Up 7.6%
The stock’s fifty day moving average price is $33.44 and its 200 day moving average price is $36.44.
About Nanobiotix
Nanobiotix is a biotechnology company developing nanoparticle-based therapies designed to improve the effectiveness of radiotherapy in cancer treatment. The company’s technology uses hafnium oxide nanoparticles that are injected directly into a tumor and activated by ionizing radiation, with the goal of increasing energy deposition within cancer cells while limiting exposure to surrounding tissue.
Nanobiotix’s lead product candidate, NBTXR3, is being evaluated in clinical studies across several cancer types, including locally advanced head and neck cancer and other solid tumors.
Featured Stories
- Five stocks we like better than Nanobiotix
- 3 Companies With Room to Pass on Costs to Manage Inflation
- Not All Tech Is Getting Crushed: 5 Names Holding Up Through the AI Sell-Off
- Actively Managed ETFs Are Giving In to the Price War—To the Benefit of Investors
- Valero’s Windfall Quarter Meets Washington’s Push for Cheaper Diesel
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
